Form 4: Hepion Pharmaceuticals Insider Buys Shares

Vincent S. LoPriore, Executive Chairman and Director of Hepion Pharmaceuticals, acquired a significant number of common shares through affiliated entities.

Summary

• Vincent S. LoPriore, in his capacity as Executive Chairman and Director of Hepion Pharmaceuticals, Inc., has reported the acquisition of common stock.
• The transactions occurred on April 21, 2026.
• 5,000,000 shares were acquired by Gravitas Capital LP, with Mr. LoPriore having voting and disposal rights.
• An additional 1,250,000 shares were acquired by the Invictus Capital Advisors Pension Plan, where Mr. LoPriore is trustee and beneficiary.
• The purchase price for these shares was $0.04 per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to significant insider buying by a key executive, indicating strong confidence in the company's prospects.

Positives

• Insider buying activity, particularly by a key executive like the Executive Chairman, can be interpreted as a positive signal of confidence in the company's future prospects.
• The acquisition of a substantial number of shares (6,250,000 in total) by Mr. LoPriore through his associated entities suggests a strong belief in the company's valuation and potential growth.
• The purchase price of $0.04 per share indicates that the acquisition was made at a relatively low valuation, potentially offering upside for the insider.

Future Outlook

This filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider buying, especially by executive leadership, is often a strong indicator of management's belief in the company's intrinsic value and future performance, particularly in the biopharmaceutical sector where significant R&D investments and clinical trial outcomes heavily influence stock prices.

Related Party Transactions

• Vincent S. LoPriore, as Managing Member of Gravitas Capital LP, has voting and disposal rights over securities held by Gravitas Capital LP.
• Vincent S. LoPriore, as trustee and beneficiary of the Invictus Capital Advisors Pension Plan, has voting and disposal rights over securities held by the Pension Plan.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially boosting confidence in the company's management and future performance.
• Employees may be encouraged by the visible commitment of executive leadership to the company's success.
• Creditors and suppliers might see this as a sign of stability and management's belief in the company's ongoing operations.

Key Dates

Recommendation

The filing reports a significant insider purchase, which is generally a positive signal. However, as this is a Form 4 reporting a past transaction and not providing new operational or financial data, a 'hold' recommendation is appropriate, suggesting investors monitor future developments and company performance rather than making immediate decisions solely based on this filing.

Keywords

Hepion Pharmaceuticals, HEPA, Form 4, Insider Trading, Stock Acquisition, Vincent S. LoPriore, Executive Chairman, Director, Gravitas Capital LP, Invictus Capital Advisors Pension Plan